Immune-Based Lymphoma Treatment Sho... (only 9.7 percent in the chemo group. ...)

Immune-Based Lymphoma Treatment Shows Promise

Date:5/31/2009

only 9.7 percent in the chemo group.

"This is amongst the first trials to show that cancer vaccines can be effective in patients," Hwu said. "This is the deadliest of skin cancers and, when it metastasizes, the median survival is less than a year. We sorely need new approaches."

"This is the first prospective randomized trial of this combination," said Dr. Margaret von Mehren, a medical oncologist with Fox Chase Cancer Center in Philadelphia. "What struck me was the six-month survival difference between the two groups. That's a really long time for metastatic melanoma."

Also at the meeting, researchers showed for the first time that trastuzumab (Herceptin) -- a highly targeted biological drug widely used to treat certain kinds of breast cancer -- may also effective in patients with advanced gastric or stomach cancers who also take chemotherapy.

"This is the first biological to show a survival benefit in an advanced gastric cancer," said study author Dr. Eric Van Cutsem, a professor with University Hospital Gasthuisberg in Leuven, Belgium. "It reduced the risk of death by 26 percent."

Herceptin targets the HER2 receptors that are found on breast cancer cells in about a quarter of patients. In this trial, the same receptor was spotted on malignant cells in about 22 percent of gastric-cancer patients, the team said.

People receiving Herceptin lived a median of 13.8 months vs. 11.1 months for those receiving chemo alone. According to Cutsem, patients with advanced stomach cancer typically only live a median of nine to 11 months.

He recommended testing for HER2 in gastric cancer patients right away. Rather than simply repeating the same trial, he pressed for trials exploring new and different ways to use the drug.

"This is an extremely important study showing that, for a significant minority of patients, the first non-cytotoxic therapy to have any kind of effectiveness against this t
'/>"/>

1

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Immune-based drug approved in Europe for pediatric cancer patients
2. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
3. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
4. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
5. January 1 Looms Large for Lymphoma Patients
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. Possible Cure for Rare Lymphoma Reported
8. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
9. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
10. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
11. Lymphoma drug used to treat skin disorders

Post Your Comments:

Immune-Based Lymphoma Treatment Sho...(only 9.7 percent in the chemo group. ...),Health